Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Sheikh Mohamed receives Arab League chief Nabil Fahmy

    November 14, 2026

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026

    digna introduces agentic AI to make enterprise data easier to understand

    November 13, 2026
    Facebook X (Twitter) Instagram
    Mashreq DailyMashreq Daily
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Mashreq DailyMashreq Daily
    Home » Federal lawsuit targets pharmacy benefit managers over insulin costs
    Health

    Federal lawsuit targets pharmacy benefit managers over insulin costs

    September 20, 2024
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    MENA Newswire News Desk: – The U.S. Federal Trade Commission (FTC) has filed a lawsuit against the three largest pharmacy benefit managers (PBMs), accusing them of inflating insulin prices and increasing costs for millions of diabetes patients. The suit, filed Friday, targets CVS’s Caremark Rx, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx. These PBMs are responsible for negotiating drug prices with manufacturers and managing which drugs are covered by insurance plans.

    Federal lawsuit targets pharmacy benefit managers over insulin costs

    According to the FTC, the PBMs artificially raised insulin prices by excluding lower-cost options from their formularies, favoring more expensive drugs with higher rebates from manufacturers. This practice has driven up the price of insulin for patients, with Eli Lilly’s Humalog insulin cited as an example. The drug’s price surged by over 1,200% between 1999 and 2017, from $21 to $274.

    FTC Deputy Director of Competition Rahul Rao emphasized that the lawsuit aims to dismantle the PBMs’ rebate system and bring about broader reforms in drug pricing. “The Big Three PBMs have profited at the expense of patients who rely on life-saving medications,” Rao said. “This lawsuit marks a crucial step toward restoring fair competition in the pharmaceutical market.”

    The FTC’s complaint also highlights the role of the PBMs’ affiliated group purchasing organizations – Zinc Health Services, Ascent Health Services, and Emisar Pharma Services in perpetuating the inflated prices. The FTC claims these organizations played a key role in maintaining high prices by creating a system that prioritized higher rebates over affordable drug options.

    While the lawsuit focuses on insulin, FTC officials noted that their goal is to overhaul drug pricing practices across the pharmaceutical industry. Anonymously, one FTC official suggested that the rebate system distorts the market by making rebates a determining factor in which drugs are included in insurance plans.

    Pharmaceutical companies and PBMs have been locked in a blame game over who is responsible for the rising cost of insulin. CVS and Express Scripts issued statements defending their practices, claiming that the FTC’s actions could lead to higher costs for patients. CVS added that its customers typically pay less than $25 per insulin dose, while Cigna’s Express Scripts called the lawsuit a politically motivated move that ignores the complex realities of drug pricing.

    Friday’s legal action stems from a two-year investigation into PBMs and insulin manufacturers. Although drug companies are not named in this case, the FTC has warned manufacturers that they could face future lawsuits over similar practices. The FTC’s move is part of the Biden administration’s broader efforts to combat rising healthcare costs, especially in the pharmaceutical sector. As insulin remains critical for millions of Americans, the lawsuit underscores the high-stakes battle over drug prices in the U.S.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026

    Dengue kills 173 in October as Bangladesh toll climbs to 418

    November 2, 2026

    Ebola death toll in DR Congo nears 4,900 as cases pass 10,000

    October 28, 2026
    Latest News

    Sheikh Mohamed receives Arab League chief Nabil Fahmy

    News November 14, 2026

    – Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, has received Arab League Secretary-General Nabil Fahmy in Abu Dhabi to discuss regional developments. The talks focused on the challenges facing the Arab world and ways to strengthen joint

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026

    Three nations launch carbon crediting initiative at COP31

    November 13, 2026

    DP World partner ATI wins 25-year Manila port renewal

    November 13, 2026

    Nigeria and EU seal readmission deal after decade of talks

    November 12, 2026

    ADB flags $264 billion yearly ASEAN infrastructure gap

    November 12, 2026

    Modi and Zelenskyy discuss peace efforts and bilateral ties

    November 11, 2026

    Amin Adam questions how Ghana will fund $10bn New Economy

    November 11, 2026
    © 2026 Mashreq Daily | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.